. Author manuscript; available in PMC: 2021 Dec 10.

Published in final edited form as: Clin Cancer Res. 2020 Jan 14;26(9):2104–2110. doi: 10.1158/1078-0432.CCR-19-2591

Table 3.

Associations between changes in bone markers and outcomes in all patients (N = 47).

Best response in bone marker^a	Radiographic Objective Response^b	PSA50 Response^c	PSA90 Response^c	Disease Control Rate^d	PSA PFS^e	Radiographic PFS^e
BAP	0.74, 95% CI (0.23, 2.40), P=0.62	1.13, 95% CI (1.39, 6.84), P=0.01	1.39, 95% CI (0.75, 2.56), P=0.29	2.11, 95% CI (0.90, 4.96), P=0.09	0.72, 95% CI (0.48, 1.06), P=0.09	0.62, 95% CI (0.39, 0.96), P=0.03
CTP	0.82, 95% CI (0.21, 3.30), P=0.78	1.32, 95% CI (0.66, 2.66), P=0.44	0.88, 95% CI (0.44, 1.76), P=0.72	5.06, 95% CI (1.44, 17.75), P=0.01	0.79, 95% CI (0.51, 1.22), P=0.29	0.68, 95% CI (0.41, 1.14), P=0.15
P1NP	1.17, 95% CI (0.35, 3.91), P=0.79	3.20, 95% CI (1.33, 7.69), P=0.01	1.51, 95% CI (0.78, 2.90), P=0.22	1.72, 95% CI (0.71, 4.15), P=0.23	0.75, 95% CI (0.52, 1.08), P=0.12	0.64, 95% CI (0.42, 0.97), P=0.04
NTP	0.72, 95% CI (0.11, 4.64), P=0.73	4.55, 95% CI (1.21, 17.13), P=0.03	1.11, 95% CI (0.39, 3.16), 0.84	17.90, 95% CI (2.14, 150.03), P=0.01	0.59, 95% CI (0.28, 1.25), P=0.17	0.43, 95% CI (0.20, 0.91), P=0.03
PYR	0.30, 95% CI (0.04, 2.39), P=0.26	1.10, 95% CI (0.34, 3.53), P=0.87	1.36, 95% CI (0.40, 4.62), P=0.63	3.86, 95% CI (0.85, 17.52), P=0.08	0.62, 95% CI (0.29, 1.32), P=0.22	0.78, 95% CI (0.36, 1.69), P=0.54

^a.

log2 baseline minus log2 final value;

^b.

Binary response (PR+CR and PD+SD), reference level of PD+SD;

^c.

Binary response of PSA50 (PSA<50, PSA≥50), and binary response of PSA90 (PSA<90, PSA≥90);

^d.

Binary radiographic disease control rate (SD+PR+CR);

^e.

Hazard ratio. Bone alkaline phosphatase (BAP), C-telopeptide (CTP), intact N-terminal propeptide (NTP), N-terminal propeptide of type 1 collagen (P1NP), and pyridinoline (PYR).